Lung cancer trials in Germany

In Germany 182 Also abroad 2733

182 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Berlin, Bonn, Chemnitz, Cologne, Dresden, Frankfurt Am Main, Gauting, Halle (saale), Hamburg, Luebeck, Munich
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
Phase 2Taking people
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Where
Bielefeld, Essen, Großhansdorf, Heidelberg, Moers, Würzburg
Age
18 years and over
People
107 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07098988 · EU 2024-516792-32-01
Phase 3Taking people
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Where
Berlin, Cologne, Dresden, Frankfurt am Main, Halle, Hamburg
Age
18 years and over
People
480 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07218146
Phase 3Not yet taking people in Germany
PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%
Where
Aachen, Augsburg, Berlin, Cologne, Dresden, Erlangen, Frankfurt am Main, Frankfurt Am Main, Giessen, Grosshansdorf, Heidelberg, Mainz, Mannheim, Munich, Oldenburg, Regensburg, Stuttgart, Tuebingen, Wuerzburg
Age
18 years and over
People
406
Run by
German Cancer Research Center
See details and how to joinNCT07877584 · EU 2026-525387-18-00
Phase 3Taking people
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Where
Cologne, Essen, Halle
Age
18 years and over
People
550 worldwide
Run by
SystImmune Inc.
See details and how to joinNCT07625644
Phase 1/2Not yet taking people in Germany
PET imaging For eaRly predictiOn of respoNse to neoadjuvanT tReatment in lUNg caNcER
Where
Tübingen
Age
18 years and over
People
40 worldwide
Run by
Radboud universitair medisch centrum Stichting
See details and how to join2025-524791-30-00
Phase 1Taking people
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Where
Berlin, Ulm, Wuerzburg
Age
18 years and over
People
300 worldwide
Run by
Kura Oncology, Inc.
See details and how to joinNCT06026410 · EU 2024-513285-19-00
Phase 3Taking people
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Where
Berlin, Bonn, Chemnitz, Duesseldorf, Esslingen am Neckar, Freiburg im Breisgau, Gauting, Gera, Grosshansdorf, Halle (saale), Kempten (Allgau), Luebeck, Mainz, Munich, Neuss, Nuremberg, Wuppertal
Age
18 years and over
People
621 worldwide
Run by
BioNTech SE
See details and how to joinNCT06712355 · EU 2024-515765-34-00
Phase 2Taking people
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
Where
Dresden, Giessen, Kassel
Age
18 years and over
People
117 worldwide
Run by
Taiho Oncology Inc.
See details and how to join2023-503865-48-00
Phase 2/3Not yet taking people in Germany
IZABRIGHT-Lung01: Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy
Where
Berlin, Chemnitz, Cologne, Donauwoerth, Esslingen am Neckar, Gauting, Hamburg, Kassel, Kiel, Stuttgart, Ulm
Age
18 years and over
People
173 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2025-521908-22-00
Phase 3Taking people
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Where
Cologne, Frankfurt am Main, Giessen, Loewenstein
Age
18 years and over
People
360 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07128199 · EU 2025-521775-31-00
Phase 2Not yet taking people in Germany
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Where
Cologne, Hamburg, Moers
Age
18 years and over
People
80 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07871214
Phase 1Taking people
Study of Elironrasib (RMC-6291) and Daraxonrasib (RMC-6236) With Other Anti-Cancer Agents in Patients With RAS G12C-Mutated NSCLC - Subprotocol A
Where
Berlin, Cologne, Dresden, Frankfurt Am Main, Heidelberg, Immenhausen, Moers
Age
18 years and over
People
330 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2023-509571-16-00
No phaseTaking people
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Where
Oldenburg
Age
18 years and over
People
14,500
Run by
AIO-Studien-gGmbH
See details and how to joinNCT02622581
No phaseTaking people
European Real-World Registry for Use of the Ion Endoluminal System
Where
Berlin, Hemer, Wiesbaden
Age
18 years and over
People
1,200 worldwide
Run by
Intuitive Surgical
See details and how to joinNCT06923774
Phase 1/2Taking people
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Where
Berlin, Essen, Mainz, München, Tübingen
Age
18 years and over
People
1,438 worldwide
Run by
BioNTech SE
See details and how to joinNCT07070232 · EU 2024-517261-16-00
Phase 2/3Taking people
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Where
Berlin, Chemnitz, Cologne, Donauwörth, Esslingen am Neckar, Gauting, Hamburg, Heidelberg, Kassel, Kiel, Oldenburg, Stuttgart, Ulm
Age
18 years and over
People
500 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07100080
Phase 1Taking people
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Where
Essen
Age
18 years and over
People
180 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07261631
Phase 3Taking people
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Where
Aschaffenburg, Berlin, Chemnitz, Duesseldorf, Frankfurt am Main, Georgsmarienhuette, Gera, Grosshansdorf, Halle (saale), Hemer, Kassel, Loewenstein, Luebeck, Moenchengladbach, Munich, Traunstein, Ulm
Age
18 years and over
People
1,410 worldwide
Run by
Pfizer
See details and how to joinNCT07222566 · EU 2025-523461-17-01
Phase 2/3Taking people
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Where
Duesseldorf, Frankfurt am Main
Age
18 years and over
People
550 worldwide
Run by
Pfizer
See details and how to joinNCT07226999 · EU 2025-523522-41-00
Phase 1/2Taking people
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Where
Düsseldorf, Frankfurt am Main, Freiburg im Breisgau
Age
18 years and over
People
162 worldwide
Run by
Pfizer
See details and how to joinNCT07227298 · EU 2025-523526-40-00
Phase 2Taking people
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Where
Duesseldorf, Grosshansdorf, Homburg, Jena, Luebeck
Age
18 years and over
People
120 worldwide
Run by
Pfizer
See details and how to joinNCT07489066 · EU 2025-524825-42-00
Phase 2Taking people
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
Where
Berlin, Tuebingen
Age
18 years and over
People
144 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Where
Berlin, Dresden, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Halle (saale), Hamburg, Hanover, Heidelberg, Homburg, Immenhausen, Karlsruhe, Leipzig, Loewenstein, Luebeck, Mannheim, Muenster, Munich, Oldenburg, Regensburg, Tuebingen, Wuerzburg
Age
18 years and over
People
282 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-518365-10-00